Combo Therapy for Advanced Melanoma, Tafinlar and Mekinist, Seen to Improve 3-Year Survival
News
Combination treatment with Novartis‘ Tafinlar (dabrafenib) and Mekinist (trametinib) improved survival of advanced myeloma patients at three years, compared to patients treated with a BRAF blocker. These findings emerged as ... Read more